Johnson & Johnson is in the final stages of analyzing clinical trial data of its coronavirus vaccine, but may not be able to deliver as many doses as promised.
The New Brunswick, New Jersey-based firm is expected to release results from its study of 40,000 volunteers in as little as two weeks.
Health experts have been excited for J&J’s vaccine because it only requires one dose as opposed to Pfizer’s and Moderna’s which are given in two doses four weeks apart.
Additionally, the vaccine has to be kept in a refrigerator as opposed to others that need to be stored in ultra-cold temperatures
But the company is facing unexpected delays in the manufacturing of its jab and may not be able to supply as many doses it promised the U.S. government by spring, reported The New York Times.
Federal officials have been told that J&J has fallen behind its original production schedule and will not catch up until the end of April, when it was supposed to deliver more than 60 million doses.
Click here to read more.
Source: Daily Mail